← Blog · Mother Health · · 9 min read
Rh-Negative Blood in Pregnancy: What Anti-D Immunoglobulin Does and Why It Matters
Rh-negative blood in pregnancy: what Rh sensitisation is and how anti-D immunoglobulin (RhoGAM) protects this baby and future pregnancies.
Approximately 15% of the population has Rh-negative blood. If you are one of them, a routine blood test early in pregnancy will have flagged this, and your provider will have mentioned something called "anti-D" or "RhoGAM." What follows is a clear explanation of what Rh negativity means, why it only becomes relevant in pregnancy, and why that injection — given at specific moments — is one of the most effective preventive treatments in modern obstetrics.
What the Rh factor actually is
The Rh factor is a protein found on the surface of red blood cells. If you have it, you are Rh-positive. If you do not, you are Rh-negative. It is inherited independently of ABO blood type, which is why someone can be A-positive, O-negative, AB-negative, and so on. There is no health advantage or disadvantage to being Rh-negative in everyday life. The issue arises only in pregnancy, when an Rh-negative mother carries an Rh-positive baby.
If the baby's father is Rh-positive — which roughly 85% of men are — there is a significant chance the baby will inherit the positive Rh gene. When that happens, small amounts of the baby's Rh-positive blood cells can cross the placenta into the mother's circulation. Her immune system, encountering a protein it does not recognize, may produce antibodies against it. This is called Rh sensitization, and once it happens, it is permanent.
Why sensitization is dangerous — but only for the next pregnancy
The first pregnancy is rarely affected. Sensitization is a slow process; antibodies typically take weeks or months to develop, and by the time they reach levels that could harm the fetus, the baby has often already been delivered. The real danger lies in subsequent pregnancies.
If an Rh-negative woman becomes sensitized and later conceives another Rh-positive baby, her pre-formed antibodies will cross the placenta and attack the fetus's red blood cells. This causes hemolytic disease of the fetus and newborn (HDFN), which can lead to:
- Anemia, sometimes severe enough to cause hydrops fetalis (fluid accumulation in tissues and organs)
- Jaundice from the breakdown of red blood cells
- In the most serious cases, stillbirth
The risk intensifies with each pregnancy. A second Rh-positive baby is usually less affected than a third or fourth. This is why preventing that first sensitization event is the entire goal of Rh management in pregnancy.
What anti-D immunoglobulin is
Anti-D immunoglobulin — known as RhoGAM in the United States and as anti-D or WinRho in other countries — is a purified solution of human antibodies against the D antigen (the Rh factor protein). It is made from the plasma of donors who have been immunized to produce these antibodies.
The mechanism is elegant. When a small fetal-maternal bleed occurs — which can happen in any pregnancy as the placenta naturally sheds tiny amounts of blood — anti-D works by binding to any Rh-positive fetal red blood cells that enter the mother's bloodstream before her own immune system notices them. Think of it as a cleanup crew that removes the evidence before the alarm is raised. Because her immune system never encounters the foreign protein, it never mounts a response. No memory B cells are activated. No antibodies are produced. She remains unsensitized.
Anti-D does not harm the baby. The antibodies are too large to cross the placenta in significant amounts, and even if trace quantities do, they do not damage fetal red blood cells the way maternal-produced antibodies would in a sensitized woman.
When it is given during pregnancy
The standard schedule varies slightly by country, but the core principle is the same: anti-D is given at routine intervals and after any event that increases the risk of fetal blood entering the maternal circulation.
Routine prophylaxis:
- At approximately 28 weeks of gestation. This is the most common single-dose approach in many countries.
- In some protocols — particularly in the United Kingdom — an earlier dose is given at 28 weeks and a second at 34 weeks.
Postnatal prophylaxis:
- Within 72 hours of delivery, if the baby is confirmed Rh-positive. A cord blood sample is tested immediately after birth to determine the baby's Rh status.
After sensitizing events during pregnancy:
- Any vaginal bleeding, including threatened miscarriage or spotting after 12 weeks
- Abdominal trauma, such as a fall or car accident
- Invasive procedures: amniocentesis, chorionic villus sampling (CVS), external cephalic version (turning a breech baby)
- Ectopic pregnancy or pregnancy termination
- Stillbirth or intrauterine death
In these situations, anti-D is given as soon as possible, ideally within 72 hours. Some guidelines allow it to be effective up to 10 days after the event, but sooner is always better.
The Kleihauer-Betke test and extra dosing
After delivery, or after any significant bleeding event, a blood test called the Kleihauer-Betke test (or flow cytometry in modern labs) is performed on the mother's blood. It measures how much fetal blood entered her circulation. If the bleed was larger than average, a standard dose of anti-D may not be enough to clear all fetal cells. In that case, an additional dose is calculated and given. This is routine after delivery in most hospitals.
If you are already sensitized
Anti-D cannot reverse sensitization. If your blood already contains anti-D antibodies — detected through an antibody screen early in pregnancy — the injection will not help. In this situation, management shifts from prevention to monitoring.
The pregnancy is followed more closely, typically with:
- Serial antibody titers to track whether antibody levels are rising
- Regular Doppler ultrasound of the fetal middle cerebral artery (MCA) to detect anemia before it becomes severe
- In some cases, intrauterine blood transfusions, where compatible donor blood is transfused directly into the umbilical vein to treat fetal anemia
- Early delivery if the fetus is mature enough and the anemia is worsening
With modern fetal medicine, even sensitized pregnancies often have good outcomes. The goal of anti-D is to make this intensive path unnecessary for the vast majority of Rh-negative women.
What you should know before receiving it
Anti-D is derived from human plasma and is screened for viruses, including hepatitis and HIV, with multiple safety steps. The risk of viral transmission is negligible. Side effects are uncommon and usually mild — soreness at the injection site, occasional low-grade fever.
Anti-D is not given to women who are already sensitized, as it provides no benefit and uses a blood product unnecessarily. It is also not given if the baby is known to be Rh-negative, since there is no D antigen to react against.
If you refuse anti-D — which some women do for personal reasons — you should understand the long-term implications. A single unsensitized pregnancy can be managed safely in future, but once sensitized, every subsequent Rh-positive pregnancy carries escalating risk.
Partners, previous children, and family history
If you are Rh-negative and your partner is Rh-negative, your baby will be Rh-negative too, and anti-D is unnecessary. If your partner's Rh status is unknown, most clinicians assume he is positive and administer anti-D accordingly, since the stakes of missing a sensitized case are high.
If you have had previous pregnancies — including miscarriages, terminations, or ectopic pregnancies — and were not given anti-D at those times, you may already be sensitized. An antibody screen at your first prenatal visit will reveal this. If you are unsure whether you received anti-D after a previous loss, tell your provider. The information matters.
The bottom line
Being Rh-negative is not a disease. It is a simple genetic trait that becomes relevant only in pregnancy, and the medicine to manage it — anti-D immunoglobulin — is one of the safest and most effective preventive treatments available. Its purpose is not to treat a problem that already exists, but to prevent one from ever forming: the silent, permanent sensitization that endangers every Rh-positive baby you carry in the future.
Take the blood tests. Accept the injections at the recommended times. And if you have any bleeding, trauma, or procedure during pregnancy, ask explicitly whether anti-D is indicated. The question may save more than one pregnancy.
Sources and further reading
- Royal College of Obstetricians and Gynaecologists (RCOG). "The Use of Anti-D Immunoglobulin for Rhesus D Prophylaxis." Green-top Guideline No. 22. www.rcog.org.uk
- American College of Obstetricians and Gynecologists (ACOG). "Prevention of Rh D Alloimmunization." Practice Bulletin No. 181. www.acog.org
- World Health Organization (WHO). "Recommendations on Prevention and Treatment of Postpartum Haemorrhage." www.who.int
- National Institute for Health and Care Excellence (NICE). "Routine antenatal anti-D prophylaxis for women who are rhesus D negative." Technology Appraisal Guidance 41. www.nice.org.uk
- Urbaniak SJ, Greiss MA. "RhD haemolytic disease of the fetus and the newborn." Blood Reviews, 2000. PubMed
- Bowman JM. "The prevention of Rh immunization." Transfusion Medicine Reviews, 1988. PubMed
This article is for educational purposes and does not replace medical advice from your obstetrician, midwife, or hematologist. If you have questions about your Rh status or anti-D, discuss them directly with your healthcare provider.
